Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.Vedolizumab (VDZ) is a selective antibody against α4β7-integrin, which targets leukocyte trafficking in the gastrointestinal tract.  The GEMINI studies are Phase 3, randomized, placebo-controlled trials to assess the efficacy of VDZ in induction and maintenance of moderately to severely active ulcerative colitis (GEMINI 1) and Crohn's disease (GEMINI 2).  GEMINI 1 showed that VDZ is an effective agent in induction and maintenance of ulcerative colitis.  GEMINI 2 met one of two primary end points in the induction phase showing that VDZ is more likely to induce clinical remission compared with placebo. 
GEMINI
Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.Vedolizumab (VDZ) is a selective antibody against α4β7-integrin, which targets leukocyte trafficking in the gastrointestinal tract.  The GEMINI studies are Phase 3, randomized, placebo-controlled trials to assess the efficacy of VDZ in induction and maintenance of moderately to severely active ulcerative colitis (GEMINI 1) and Crohn's disease (GEMINI 2).  GEMINI 1 showed that VDZ is an effective agent in induction and maintenance of ulcerative colitis.  GEMINI 2 met one of two primary end points in the induction phase showing that VDZ is more likely to induce clinical remission compared with placebo. 
GEMINI
Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.Vedolizumab (VDZ) is a selective antibody against α4β7-integrin, which targets leukocyte trafficking in the gastrointestinal tract.  The GEMINI studies are Phase 3, randomized, placebo-controlled trials to assess the efficacy of VDZ in induction and maintenance of moderately to severely active ulcerative colitis (GEMINI 1) and Crohn's disease (GEMINI 2).  GEMINI 1 showed that VDZ is an effective agent in induction and maintenance of ulcerative colitis.  GEMINI 2 met one of two primary end points in the induction phase showing that VDZ is more likely to induce clinical remission compared with placebo. 
GEMINI
Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.Vedolizumab (VDZ) is a selective antibody against α4β7-integrin, which targets leukocyte trafficking in the gastrointestinal tract.  The GEMINI studies are Phase 3, randomized, placebo-controlled trials to assess the efficacy of VDZ in induction and maintenance of moderately to severely active ulcerative colitis (GEMINI 1) and Crohn's disease (GEMINI 2).  GEMINI 1 showed that VDZ is an effective agent in induction and maintenance of ulcerative colitis.  GEMINI 2 met one of two primary end points in the induction phase showing that VDZ is more likely to induce clinical remission compared with placebo. 
GEMINI